MDxHealth SA（MDXH）股票分析MDXHMDxHealth SA

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States. It operates in the Healthcare sector.

MDxHealth SA is not a good buy right now due to its extremely low current price of $0.18, a very low RSI of 16.424 indicating oversold conditions, and a staggering year-to-date change of -94.66%. The company is facing serious financial challenges, including a net income loss of $11.5 million in Q2 2026 and a risk of delisting from Nasdaq if it fails to meet compliance by December 2026. The main risk is the company's inability to regain compliance with Nasdaq, which could severely impact its market credibility and financing capabilities.